How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) issued its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) EPS for the quarter.

When did OHR Pharmaceutical's stock split?

OHR Pharmaceutical shares reverse split on the morning of Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OHR Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM) , TherapeuticsMD (TXMD) , Cytori Therapeutics (CYTX) , Synergy Pharmaceuticals (SGYP) , IVERIC bio (OPHT) , Novavax (NVAX) , Immunomedics (IMMU) , OPKO Health (OPK) , Dynavax Technologies (DVAX) and Energy Transfer (ET) .

NASDAQ:OHRP

OHR Pharmaceutical (OHRP) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free OHRP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.40
▼
$0.44
50-Day Range: $5.39
▼
$9.07
52-Week Range: $1.60
▼
$6.28

Volume: 30,890 shs
Average Volume: 180,228 shs
Market Capitalization: $1.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get OHR Pharmaceutical alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About OHR Pharmaceutical Stock (NASDAQ:OHRP)

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

OHRP Stock News Headlines

April 14, 2024 | benzinga.com

Pharmaceutical Stocks

March 17, 2024 | seekingalpha.com

CYCC Cyclacel Pharmaceuticals, Inc.

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 12, 2021 | ca.finance.yahoo.com

OHR Pharmaceutical (OHRP) is now in Oversold Territory

See More Headlines

Receive OHRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OHR Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2018
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OHRP
CUSIP: N/A
CIK: 1173281
Web: www.ohrpharmaceutical.com
Phone: 212-682-8452
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,230,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -75.46%
Return on Assets: -71.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.73
Quick Ratio: 3.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.86 per share
Price / Book: 0.11

Miscellaneous

Outstanding Shares: 2,829,000
Free Float: N/A
Market Cap: $1.19 million
Optionable: Not Optionable
Beta: 0.84

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Jason Scott Slakter (Age 61)
CEO, Pres & Director
Mr. Samuel Backenroth (Age 35)
CFO, VP of Bus. Devel. & Sec.
Dr. Glenn L. Stoller M.D. (Age 55)
Chief Scientific Officer
Dr. Marlene Modi
Head of Preclinical & Regulatory Affairs

Key Competitors

View All Competitors

OHRP Stock Analysis - Frequently Asked Questions

How were OHR Pharmaceutical's earnings last quarter?: OHR Pharmaceutical Inc (NASDAQ:OHRP) issued its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) EPS for the quarter.
When did OHR Pharmaceutical's stock split?: OHR Pharmaceutical shares reverse split on the morning of Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of OHR Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), IVERIC bio (OPHT), Novavax (NVAX), Immunomedics (IMMU), OPKO Health (OPK), Dynavax Technologies (DVAX) and Energy Transfer (ET).

This page (NASDAQ:OHRP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OHR Pharmaceutical (OHRP) Stock Price, News & Analysis

About OHR Pharmaceutical Stock (NASDAQ:OHRP)

OHRP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OHRP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info